ESTRO 2024 - Abstract Book

S5640

RTT - Patient experience and quality of life

ESTRO 2024

Figure 2 presents a summary of the dose-volume histogram (DVH) values for the first 100 patients treated with SABR between 2020-2022. These values have been categorized based on the relative CTV/PTV coverage to rectal and bladder doses.

Conclusion:

To conclude, toxicity scores matched that observed in the PACE-B trial 2-year reported results. Generally, the spread of the data was not significant, and the majority remained as having grade 0 toxicity. The DVH values reported suggest that whilst a larger margin was used when compared to PACE-B, comparable OAR constraints and PROMS could be achieved.

It is acknowledged, that there is a small number of patients at 2 years and therefore it is recommended to complete further analysis at a later stage for a larger sample and more reliable results.